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a b s t r a c t
Objective: To analyze trends in utilization of anti-thrombotic agents (ATA) and in-hospital
clinical outcomes in non-ST-elevation myocardial infarction (NSTEMI) patients managed
with an invasive strategy from 2007 to 2010.
Methods & results: Using ACTION Registry®-GWTGTM data, we analyzed trends in use of ATA
and in-hospital clinical outcomes among 64,199 NSTEMI patients managed invasively
between 2007 and 2010. ATA included unfractionated heparin (UFH), low molecular weight
heparin (LMWH), glycoprotein IIb/IIIa inhibitors (GPI) and bivalirudin. Although the propor-
tion of NSTEMI patients treated with PCI within 48 h of hospital arrival was similar in 2007
and 2010, percentage use of bivalirudin (13.4–27.3%; p < 0.01) and UFH increased (60.0–67.5%,
p < 0.01), and that of GPI (62.3–41.0%; p < 0.01) and LMWH (41.5–36.8%; p < 0.01) declined.
Excess dosing of UFH (75.9–59.3%, p < 0.01), LMWH (9.6–5.2%; p < 0.01) and GPI (8.9–5.9%,
p < 0.01) was also signiﬁcantly lower in 2010 compared with 2007. Though in-hospital
mortality rates were similar in 2007 and 2010 (2.3–1.9%, p = 0.08), the rates of in-hospital
major bleeding (8.7–6.6%, p < 0.01) and non-CABG related RBC transfusion (6.3–4.6%, p < 0.01)
were signiﬁcantly lower in 2010 compared with 2007.
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Conclusion: Compared with 2007, patients with NSTEMI, who were managed invasively in
2010 received GPI and LMWH less often and bivalirudin and UFH more frequently. There
were sizeable reductions in the rates of excess dosing of UFH (though still occurred in 67% of
patients), GPI and LMWH. In-hospital major bleeding complications and post-procedural
RBC transfusion were lower in 2010 compared with 2007.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 4 6 4 – 4 7 2 4651. Introduction
Anti-thrombotic agents (ATA) are the cornerstone for treat-
ment of non-ST-segment elevation myocardial infarction
(NSTEMI).1,2 Parenteral anticoagulants and concomitant GP
IIb/IIIa inhibitors (GPI) prevent recurrent ischemic events and
peri-procedural myocardial infarction (MI) among patients
with NSTEMI.3,4 However, due to the inherent nature of an
invasive procedure coupled with use of anticoagulants, this
ischemic beneﬁt is accompanied by increased bleeding risk.
Numerous studies have shown worse clinical outcomes,
including mortality, among patients with major in-hospital
bleeding complications.5–7 Hence, bleeding avoidance strate-
gies have received considerable attention as increased focus
has been placed on patient safety. These include alternative
approaches for vascular access and access site hemostasis,
appropriate dosing of antithrombotic medications and selec-
tion of antithrombotic strategies with lower bleeding risk
proﬁles. In the last few years, landmark trials such as
REPLACE-2 (The Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Events), ACUITY (Acute Cathe-
terization and Urgent Intervention Triage Strategy), ISAR-
REACT 3 (Intracoronary Stenting and Antithrombotic Regi-
men—Rapid Early Action for Coronary Treatment 3) and
EARLY-ACS (Early Glycoprotein IIb/IIIa Inhibition in non-ST-
segment elevation acute coronary syndrome) have provided a
better understanding of the risks and beneﬁts of anti-
thrombotic therapy for acute coronary syndrome (ACS)
patients undergoing PCI.8–12 Although these clinical trials
have offered insights into selection of antithrombotic agents
for NSTEMI patients, patterns of use of these agents (type of
agent and frequency of excess dosing) and outcomes among
NSTEMI patients following the publication of these key trials
have not yet been analyzed. Hence, our study used data from
the National Cardiovascular Data Registry's (NCDR) ACTION
Registry®-GWTGTM (ACTION Registry® – Get with the Guide-
linesTM) from 2007 to 2010 to analyze the use of intravenous
antithrombotic agents among NSTEMI patients managed with
an invasive strategy and to further examine in-hospital
ischemic and bleeding outcomes during this period.
2. Methods
2.1. Registry
The NDCR ACTION Registry®-GWTGTM is a national quality
improvement registry of ST-segment elevation myocardialinfarction (STEMI) and NSTEMI patients who began enrolling
on January 1, 2007.13 Patients are eligible for inclusion in
ACTION, if they present within 24 h from onset of ischemic
symptoms and receive a primary diagnosis of NSTEMI or
STEMI.
De-identiﬁed data are extracted from existing medical
records onto a web-based case form by trained data collectors
at each center. Study participation at each center was
approved by local institutional review boards. The NCDR
has a data quality program in place to ensure consistent and
reliable data. Quality assurance measures, such as data quality
reports and random site audits by trained nurse abstractors,
are used to maximize the completeness and accuracy of all
records submitted.
2.2. Study population
Starting from 158,540 NSTEMI patients enrolled in 569 US
hospitals of ACTION Registry®-GWTGTM from January 1, 2007
to December 31, 2010, the following patients were excluded
sequentially: Patients in centers using limited data collection
form (DCF) (n = 10, 346), patients managed medically (n = 35,
705), transfer-out patients (n = 3, 475), patients in hospitals
without PCI capability (n = 3, 021 in 49 centers), dialysis
patients (n = 2884), patients from hospitals that did not enroll
patients consecutively annually (n = 32,627), and patients from
hospitals entering fewer than 25 patients annually (n = 6283 in
37 centers). Thus, the ﬁnal analysis population consisted of
64,199 patients from 100 ACTION Registry®-GWTGTM centers.
2.3. Deﬁnitions of antithrombotic agents and excess
dosing
Use of unfractionated heparin (UFH) or low molecular weight
heparin (LMWH) was deﬁned as use on the day of or the day
immediately following admission without the use of other
anticoagulants during that period or having the agent initiated
after arrival in the cardiac catheterization laboratory. We
examined only the use of small molecule GPI (eptiﬁbatide or
tiroﬁban) and deﬁned use as initiation on the day of or the day
immediately following hospital arrival.
Standardized dosing regimens recommended in the ACC/
AHA guidelines for unstable angina/NSTEMI14 were used to
deﬁne appropriate and excess dosing of each antithrombotic
agent (except bivalirudin). Excess dosing for intravenous UFH
was deﬁned as: a bolus dose >60 units/kg (max 4000 units) or
infusion >12 units/kg/h (max 1000 units/h). The recom-
mended daily dose of enoxaparin sodium was (1 mg/kg bid)
for patients with a creatinine clearance of ≥30 mL/min and
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The patient's recorded body weight was used for this
calculation. If the administered daily dose exceeded the
recommended daily dose by more than 10 mg, the patient
was categorized as having received an ‘‘excess’’ dose of
enoxaparin.15 For glycoprotein IIb/IIIa inhibitor, failure to
appropriately reduce doses for creatinine clearance. For
eptiﬁbatide, full dose infusion was deﬁned as 2 mg/kg/min,
with reduced dose of 1 mg/kg/min for patients with creatinine
clearance <50 mL/min. For tiroﬁban, full dose infusion was
deﬁned as 0.1 mg/kg/min, with reduced dose of 0.05 mg/kg/min
for patients with creatinine clearance <30 mL/min. Creati-
nine clearance was estimated using the Cockcroft-Gault
equation from age, gender, creatinine and weight. ‘‘Pre-
procedure/Planned/Upstream’’ use of GPI was deﬁned as any
use from clinical presentation up to an hour before the PCI.
‘‘Peri-procedural/Provisional/Downstream’’ use of GPI was
deﬁned as 1-hour pre-procedure use to any time during or
after procedure. Other study deﬁnitions are available at the
NCDR website http://www.ncdr.com/WebNCDR/ACTION/
Elements.aspx. Patients with missing dosing information
were excluded.
2.4. Deﬁnitions of in-hospital clinical outcomes
The ACTION major bleeding deﬁnition has been validated
previously,16 and includes an absolute hemoglobin (Hb) drop of
≥4 g/dL (initial value to nadir during hospitalization), intracra-
nial hemorrhage, documented or suspected retroperitoneal
bleed, any RBC transfusion with baseline Hb ≥9 g/dL, or any
RBC transfusion with Hb <9 g/dL and a suspected bleeding
event. Given that a majority of patients undergoing coronary
bypass graft surgery (CABG) receive blood transfusions related
to the surgery, bleeding events for these patients were
considered only if they occurred prior to CABG. A suspected
bleeding event was deﬁned as any of the following: (a) Hb drop
of ≥3 g/dL, (b) transfusion of whole blood or packed RBCs, (c)
procedural intervention/surgery at the bleeding site to reverse,
stop or correct the bleeding (such as surgical closures/
exploration of the arteriotomy site, balloon angioplasty to
seal an arterial tear, endoscopy with cautery of a GI bleed).
Blood transfusion was deﬁned as any non-autologous trans-
fusion of whole or packed RBCs. Other outcome deﬁnitions are
available at the NCDR website http://www.ncdr.com/
WebNCDR/ACTION/Elements.aspx.
2.5. Statistical analysis
Patient baseline characteristics, clinical factors, treatment
patterns, and in-hospital outcomes were stratiﬁed by year of
patient hospital arrival. Continuous variables were described
as means (standard deviation), and categorical variables were
expressed as frequencies with percentages. The Kruskal–
Wallis test was used to determine whether there were any
differences between continuous or ordinal variables between
years, and the Pearson chi-square test was used to determine if
there were any differences in categorical variables between
years.
Furthermore, trends in use of antithrombotic agents,
excess dosing of these agents, in-hospital all-cause mortalityand major bleeding were explored. The p-values testing for
linear trends of use of antithrombotic agents, excess dosing
and in-hospital outcomes were obtained by modeling year of
patient hospital arrival as an ordinal independent variable
using the logistic generalized estimating equations method
with an exchangeable working correlation matrix to account
for within-hospital clustering because patients at the same
hospital are more likely to have similar outcomes relative to
patients at other hospitals (i.e., within-center correlation for
outcomes).17 This method produces estimates similar to those
from logistic regression, but their variances are adjusted for
the correlation of outcomes within a hospital. A p-value <0.05
was considered statistically signiﬁcant for all tests. All
analyses were performed using SAS software (version 9.3,
SAS Institute, Cary, North Carolina, U.S.).
3. Results
Patient demographic characteristics according to year of
patient enrollment appear in Table 1. Mean age and sex
distribution remained comparable from 2007 to 2010.
Medical history and clinical characteristics at presentation
by year of patient admission are presented in Table 2. The
proportion of patients with hypertension, dyslipidemia,
diabetes, and prior history of MI, congestive heart failure
(CHF), percutaneous coronary intervention (PCI) and periph-
eral arterial disease (PAD) increased (statistically signiﬁcant
but most differences were small) each year from 2007 until
2010. The time to symptom onset to arrival time decreased
over the span of four years (from 7 to 5.2 h, p < 0.01).
Medication use within 24 h of presentation is presented in
Table 3.
3.1. Trends in use of antithrombotic agents
Trends in antithrombotic agent use are depicted in Fig. 1.
Although the proportion of NSTEMI patients treated with PCI
within 48 h of hospital arrival was similar in 2007 and 2010
(51.1–51.8%, p = 0.19), there was a signiﬁcant increase in the
use of bivalirudin (13.4–27.3%, p < 0.01). A similar trend was
also seen with UFH (60.0–67.5%, p < 0.01). Conversely, the use
of LMWH (41.5–36.8%, p = 0.03) and GPI (62.3–41.0%, p < 0.01)
declined during the same time period. Among patients treated
with GPI there was also a modest decline in proportion of ‘‘pre-
procedural/planned/upstream’’ use (49.2–44.4%, p < 0.01) from
2007 to 2010. Among patients receiving GPI, a signiﬁcant
decline in the mean duration of therapy was observed during
the same time period (23 h and 32 min to 20 h and 47 min,
p < 0.01).
3.2. Trends of excess dosing of antithrombotic agents
Trends of excess dosing of antithrombotic agents are shown in
Fig. 2 and Table 4. There was a signiﬁcant decline in the rates of
excess dosing of GPI (8.9–5.9%, p < 0.01). Rates of excess dosing
of UFH declined from 75.9% in 2007 to 59.3% in 2010 (Table 4).
Though there was no decline in excess dosing of the initial
bolus (27.0% in 2007 to 22.0% in 2010, p = 0.21) a signiﬁcant
increase in excess dosing of the infusion (10.4% in 2007 to
Table 1 – Demographic characteristics by year of patient enrollment.
Variable Overall (n = 64,199) 2007 (n = 14,498) 2008 (n = 16,317) 2009 (n = 16,759) 2010 (n = 16,625) p-Value
Age (years) 63.6  13.1 63.7  13.1 63.4  13.2 63.7  13.0 63.7  13.1 0.45
Males (%) 65.6 65.5 65.5 65.9 65.6 0.70
Weight (kg) 88.1  21.6 87.7  21.4 88.0  21.5 88.3  21.5 88.4  22.1 <0.01
Body mass index (kg/m2) 29.9  6.7 29.8  6.7 29.8  6.7 29.9  6.7 30.0  6.8 <0.01
Race (%)
Caucasian 85.4 86.6 85.1 85.2 85.0 <0.01
Black 9.0 8.2 8.8 9.3 9.7
Asian 1.0 1.0 0.9 1.0 1.2
Hispanic 2.7 2.2 2.8 2.8 2.8
Other 1.2 1.7 1.6 0.9 0.7
Insurance status (%)
HMOa/private 58.0 56.5 57.6 57.9 60.0 <0.01
Medicare 26.6 28.9 27.9 26.2 23.8
Military/VAb 1.6 1.6 1.7 1.7 1.5
Medicaid 3.5 3.3 3.3 3.8 3.7
Self/none 9.5 9.2 8.9 9.7 10.2
Other 0.5 0.0 0.3 0.8 0.8
Data are expressed as means  standard deviations or percentages.
a HMO – health maintenance organizations.
b VA – veterans affairs.
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period. The proportion of patients who received an excess dose
of both the bolus and infusion declined during the same time
period (38.5% in 2007 to 20.7% in 2010, p < 0.01). Changes in
mean dosing are depicted in detail in Table 4.
Excess dosing of LMWH also showed declined during the





Smoking (<1 year) (%) 35.0 34.4 
Hypertension (%) 73.2 70.9 
Dyslipidemia (%) 62.8 60.0 
Chronic lung disease (%) 14.1 N/A 
Diabetes mellitus (%) 31.6 30.9 
Prior myocardial infarction (%) 26.1 25.3 
Prior CHFa (%) 10.3 9.7 
Prior PCIb (%) 25.9 24.2 
Prior CABGc (%) 17.2 17.2 
Prior revascularization (%) 34.9 33.3 
Atrial ﬁb/ﬂutter (<2 weeks) (%) 6.0 N/A 
Cerebrovascular disease (%) 11.4 N/A 
Prior stroke (overall) (%) 7.1 6.9 
Peripheral arterial disease (%) 10.0 9.2 
ECGd ﬁndings (%)
ST depression/transient ST elevation 29.5 32.6 
T-wave inversion 15.7 12.9 
None 54.8 54.5 
Symptom onset to arrival (h) 5.7  11.8 7.0  20.0
Signs of CHF (%) 14.1 14.6 
Cardiogenic shock (%) 1.3 1.0 
a CHF – congestive heart failure.
b PCI – percutaneous coronary intervention.
c CABG – coronary artery bypass surgery.
d ECG – Electrocardiogram.3.3. In-hospital clinical outcomes
In-hospital clinical outcomes for each year of patient hospital
arrival are presented in Fig. 3. Rates of major bleeding (8.7–
6.6%, p < 0.01), requirement of RBC transfusion among non-
CABG patients (6.3–4.6%, p < 0.01), and any suspected bleeding








35.4 35.3 35.0 0.38
72.9 74.1 74.8 <0.01
61.8 64.6 64.5 <0.01
14.4 14.2 13.8 0.16
31.0 32.1 32.2 <0.01
26.3 26.5 26.3 0.04
10.2 10.5 10.7 <0.01
26.0 26.6 26.6 <0.01
17.6 16.9 17.3 0.88
35.0 35.4 35.6 <0.01
6.2 6.0 5.8 0.25
11.3 11.5 11.4 0.86
7.2 7.4 6.7 0.70
10.0 10.1 10.4 <0.01
30.7 28.0 27.2 <0.01
15.1 17.4 17.0
54.3 54.6 55.9
 6.0  13.9 4.9  5.6 5.2  7.1 <0.01
14.1 13.7 14.0 0.12
1.2 1.5 1.4 <0.01
Table 3 – Medication use within 24 h of hospital arrival by year of patient enrollment.
Variable Overall (n = 64,199) 2007 (n = 14,498) 2008 (n = 16,317) 2009 (n = 16,759) 2010 (n = 16,625)
Aspirin (%) 98.1 97.8 97.8 98.3 98.4
Clopidogrel (%) 64.6 66.5 66.9 65.0 60.6
Any oral antiplatelet (%) 98.2 98.2 98.0 98.1 98.4
Ticlopidine (%) 0.2 N/A 0.2 0.2 0.1
Prasugrel (%) 2.7 N/A 0.0 0.6 6.1
Beta blocker (%) 92.2 94.5 93.6 91.3 89.6
ACEa inhibitor (%) 44.5 47.7 45.6 43.1 42.0
ARBb (%) 8.8 9.3 9.0 8.8 8.1
ACE inhibitor or ARB (%) 50.0 52.6 51.0 49.2 47.7
Aldosterone blocking agent (%) 1.8 2.2 1.8 1.7 1.7
Statin 63.7 61.9 63.5 64.1 65.1
Other lipid-lowering agent 8.9 10.2 8.8 8.4 8.2
Any lipid-lowering agent 64.5 63.1 64.3 64.8 65.5
All comparisons were p < 0.01 except for any oral antiplatelet, and ticlopidine.
a ACE – angiotensin converting enzyme.
b ARB – angiotensin receptor blocker.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 4 6 4 – 4 7 2468a non-signiﬁcant trend toward declining all-cause mortality
(2.3–1.9%, p = 0.08).
4. Discussion
Derived from a large, multicenter national registry, use of
antithrombotic agents from 2007 to 2010 revealed a decline in
the use of GPI and LMWH among patients with NSTEMI
managed with an invasive strategy. However, there was an
increase in use of UFH and bivalirudin during the same time
period. We also observed a signiﬁcant reduction in excess
dosing of UFH and GPIs during the same time period.All comparison  were  p(trend ) < 0.01   




























Fig. 1 – Trends in use of antithrombotic agents by year of patien
unfractionated heparin; LMWH – low molecular weight heparin;Furthermore, there was a signiﬁcant decline in major bleeding
complications during index hospitalization. Our study con-
ﬁrms the changing trends in use of antithrombotic agents,
reductions in excess dosing, and bleeding events in recent
years among NSTEMI patients.18
4.1. Impact of landmark trials – choice of anticoagulation
Our data reﬂects 4 recent years of ATA usage in the management
of NSTEMI patients treated invasively, and represents impor-
tant changing trends in cardiology practice. Contemporary trials
have conﬁrmed the safety and efﬁcacy of heparin and













t enrollment. All comparisons were p(trend) < 0.01. UFH –
 GPI – glycoprotein IIb/IIa inhibitors.














Fig. 2 – Trends in ‘‘excess use’’ of antithrombotic agents by year of patient enrollment. GPI – glycoprotein IIb/IIIa inhibitors;
LMWH – low molecular weight heparin; UFH – unfractionated heparin.
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GPI.9,11,12,20,21. The early impact of these studies on contempo-
rary practice can be gauged from the trends depicted in a recent
publication22 and more explicitly in our study. Lopes et al.
showed that NSTEMI patients undergoing PCI were more likely
to receive bivalirudin or heparin alone when presenting with a
high baseline bleeding risk.22 Our study conﬁrms both anTable 4 – Trends in excess dosing of antithrombotic agents by
Variable Overall
(n = 64,199) (n
(A) Excess dosing of GPIa
Excess GPI (%) 7.4 
Length of GPI therapy for all patients (min) 1357  1085 141
(B) Excess dosing of LMWHb
Excess LMWH (%) 7.2 
(C) Excess dosing of UFHc trends
Excess UFH (%) 66.9 
Bolus UFH dose only (%) 24.3 
Infusion UFH dose only (%) 13.3 
Bolus & Infusion UFH dose (%) 29.3 
(D) UFH mean dose
Bolus dose only (U) 5095  818 51
Infusion dose only (U/h) 1103  273 11
Bolus dose among both excess (U) 5517  1391 557
Infusion dose among both excess (U/h) 1187  297 12
All comparisons were p < 0.01 except for bolus UFH dose only.
a GPI – glycoprotein IIb/IIIa inhibitors.
b LMWH – low molecular weight heparin.
c UFH – unfractionated heparin.increasing trend of UFH and bivalirudin and a distinct declining
trend of GPI and LMWH use from 2007 to 2010. These ﬁndings
may reﬂect the impact of prior landmark trials on our current
practices to minimize bleeding events. It is also of interest that
increasing use of bivalirudin appears to be occurring at the
expense of LMWH rather than UFH, as overall UFH usage has









8.9 7.4 7.2 5.9
2  1067 1411  1102 1345  1091 1247  1067
9.6 8.4 6.1 5.2
75.9 71.7 63.4 59.3
27.0 26.3 22.5 22.0
10.4 11.8 13.6 16.6
38.5 33.5 27.3 20.7
08  752 5256  1113 5037  656 4970  594
61  341 1084  239 1091  259 1096  264
7  1290 5692  1529 5395  1274 5337  1428
08  299 1202  294 1173  284 1153  314
Fig. 3 – Trends in in-hospital clinical outcomes by year of
patient enrollment. RBC – red cell transfusion. CABG –
coronary artery bypass surgery.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 4 6 4 – 4 7 24704.2. Excess dosing of antithrombotic agents
Despite observing favorable changes in clinical practice with
respect to excess doing of antithrombotic agents, particularly
for UFH (the most frequently used antithrombotic agent),
about two third of patients still received a mean initial dose of
UFH substantially greater than the maximum recommended
4000 U and a mean infusion substantially higher than the
maximum recommended 1000 U/h. Therefore, there remains a
clear opportunity to improve adherence to UFH dosing
guidelines. The remarkably high rate of excess UFH dosing
may reﬂect either a knowledge gap or uncertainty regarding
currently recommended UFH dosing in U.S. Guidelines.
Although the U.S. dosing guidelines for UFH in UA/NSTEMI
changed in 20071 to the currently recommended dose regimen,
it is notable that no are provided in this guideline to support
the change to this lower-dose regimen of UFH. Thus, the large
discrepancy between clinical practice and the current guide-
line recommendation may also reﬂect uncertainty among
practitioners regarding the 4000 U maximum bolus in UA/
NSTEMI, particularly for obese individuals. Additional data are
needed to determine optimal initial UFH dosing in UA/NSTEMI.
Our study also showed approximately 40% relative reduc-
tions in the rates of excess dosing of GPI (38%) and LMWH (46%)
from 2007 to 2010. Patients with excess dosing of UFH, LMWH,
and GPI have higher risks for major bleeding and hemorrhagic
complications that increase relative to the degree of excess dose
and number of agents dosed excessively.23 Despite increasing
prevalence of clinical characteristics associated with excess
dosing of antithrombotic agents and bleeding (from 2007 to
2010) within our study sample, rates of excess dosing and
bleeding both declined during the period we studied. These
observations support the hypothesis that implementation of
guidelines into clinical practice has the potential to signiﬁcantly
impact care practices and clinical outcomes.please add this reference. I had it in my original submission,
dont see it here.Dasari TW, Golwala H, Koehler M, et al. Is risk
factor control and guideline-based medical therapy optimal in
patients with nonobstructive coronary artery disease? A
Veterans Affairs study. Am J Med Sci.May 2013;345(5):339-342.
4.3. Timing of GPI
Our study revealed a marked decline in overall GPI use, but
with only a modest reduction in the proportion of patients
receiving GPI as ‘‘upstream’’ therapy (49.2–44.4%, p < 0.01),
despite the results from the EARLY ACS and ACUITY trials that
revealed no incremental beneﬁt on ischemic events and higher
bleeding rates with upstream use.8,10
4.4. Decline in bleeding events
Bleeding is an independent predictor of adverse outcomes that
can be modiﬁed.6,7,24 The changes in use of antithrombotic
strategies in our study may reﬂect attempts to employ strategies
to mitigate bleeding risks. In addition to an increased preference
to use of bivalirudin, there was a decline in GPI use from 2007 to
2010, associated with slightly less upstream use, and lower rates
of excess dosing of UFH, LMWH and GPI, all of which again may
have contributed to the declining bleeding rates observed in our
study. However, our study also highlights that considerable
improvement may still be possible, particularly with respect to
excess dosing of UFH. Though ACTION Registry®-GWTGTMdoes
not collect data on proportion of radial access, it is possible that
an increase in adoption of radial access or other process factors
over the last 4 years also may have contributed favorably to
improvement in bleeding outcomes that we observed.
5. Study limitations
Our study has several limitations. The hospitals participate in
the ACTION Registry®-GWTGTM initiative voluntarily; and
hence this database may not be a representation of national
practices. The outcomes reported in this observational study
reﬂect in-hospital outcomes; therefore, caution should be
taken when considering the long-term implications of these
results. Further, although there are standardization and
uniformity in ACTION Registry®-GWTGTM data collection,
quality control and participant feedback, any large national
database effort is inherently imperfect. This study was not
designed to analyze results by race and ethnicity, and hence
variations in utilization of ATAs and outcomes by race as seen
in several cardiovascular studies cannot be interpreted from
the results of this study. The ACTION Registry®-GWTGTM does
not have data pertaining to bivalirudin dosing; thus, analysis
of excess dosing of bivalirudin could not be ascertained.
Finally, the exact timing of or switching between antithrom-
botic agents was not considered.
6. Conclusion
Compared with 2007, patients with NSTEMI, who were
managed invasively in 2010 less often received GPI and LMWH
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 4 6 4 – 4 7 2 471and more frequently received bivalirudin and UFH. There were
sizeable reductions in the rates of excess dosing of UFH, GPI
and LMWH. Although excess dosing of UFH declined substan-
tially, it still occurred about 67% of patients. In-hospital major
bleeding complications and post-procedural RBC transfusion
were lower in 2010 compared with 2007.
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Signiﬁcance of our study
Our study conﬁrms the changing trends in use of antithrom-
botic agents, with a decline in agents known to predispose
patients to bleeding (GPI) and an increased utilization of
agents that afford a favorable bleeding proﬁle (bivalirudin).
These ﬁndings may reﬂect the impact of prior landmark trials
on our current practices to minimize bleeding events. Also,
our study has shown a heartening trend of reductions in
excess dosing, and bleeding events in recent years among
NSTEMI patients. These observations support the hypothesisthat implementation of guidelines into clinical practice has
the potential to signiﬁcantly impact care practices and
clinical outcomes.
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